Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brno, Czech Republic, 656 91
- Pfizer Investigational Site
-
Brno, Czech Republic, 656 53
- Pfizer Investigational Site
-
Brno, Czech Republic, 625 00
- Pfizer Investigational Site
-
Ceske Budejovice, Czech Republic, 370 87
- Pfizer Investigational Site
-
Chomutov, Czech Republic, 430 12
- Pfizer Investigational Site
-
Hradec kralove, Czech Republic, 500 05
- Pfizer Investigational Site
-
Jihlava, Czech Republic, 586 33
- Pfizer Investigational Site
-
Karvina, Czech Republic, 735 06
- Pfizer Investigational Site
-
Liberec, Czech Republic, 460 63
- Pfizer Investigational Site
-
Nova Ves pod Plesi, Czech Republic, 26204
- Pfizer Investigational Site
-
Novy Jicin, Czech Republic, 741 01
- Pfizer Investigational Site
-
Ostrava, Czech Republic, 703 84
- Pfizer Investigational Site
-
Ostrava, Czech Republic, 708 52
- Pfizer Investigational Site
-
Pardubice, Czech Republic, 532 03
- Pfizer Investigational Site
-
Plzen, Czech Republic, 301 00
- Pfizer Investigational Site
-
Praha, Czech Republic, 100 34
- Pfizer Investigational Site
-
Praha, Czech Republic, 128 08
- Pfizer Investigational Site
-
Praha, Czech Republic, 140 59
- Pfizer Investigational Site
-
Praha, Czech Republic, 150 00
- Pfizer Investigational Site
-
Praha 5, Czech Republic, 150 00
- Pfizer Investigational Site
-
Zlin, Czech Republic, 639 00
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with advanced or metastatic renal cell carcinoma.
Exclusion Criteria:
- No previous cytokines therapy.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients treated with SUTENT®
Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
|
SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period.
Sutent is administered until disease progression or occurrence of unacceptable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Objective Response
Time Frame: 12 months
|
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR).
CR is defined as the disappearance of all target lesions.
PR is defined as at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
|
12 months
|
|
Progression-free Survival (PFS)
Time Frame: Baseline to measured progressive disease (up to 12 months)
|
The period from study entry until disease progression, death, or date of last contact.
|
Baseline to measured progressive disease (up to 12 months)
|
|
Overall Survival (OS)
Time Frame: Baseline to date of death (up to 12 months)
|
OS is the duration from enrollment to death.
|
Baseline to date of death (up to 12 months)
|
|
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Week 6
Time Frame: Week 6
|
Following are ECOG grades.
0: Fully active, perform all pre-disease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature.
2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours.
3: Capable of limited selfcare, confined to bed or chair >50% of waking hours.
4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.
5: Dead.
Participants in "Not reported" category were on study, had no data for this time point.
|
Week 6
|
|
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Month 3
Time Frame: Month 3
|
Following are ECOG grades.
0: Fully active, perform all pre-disease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature.
2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours.
3: Capable of limited selfcare, confined to bed or chair >50% of waking hours.
4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.
5: Dead.
Participants in "Not reported" category were on study, had no data for this time point.
|
Month 3
|
|
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Month 6
Time Frame: Month 6
|
Following are ECOG grades.
0: Fully active, perform all pre-disease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature.
2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours.
3: Capable of limited selfcare, confined to bed or chair >50% of waking hours.
4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.
5: Dead.
Participants in "Not reported" category were on study, had no data for this time point.
|
Month 6
|
|
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Month 9
Time Frame: Month 9
|
Following are ECOG grades.
0: Fully active, perform all pre-disease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature.
2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours.
3: Capable of limited selfcare, confined to bed or chair >50% of waking hours.
4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.
5: Dead.
Participants in "Not reported" category were on study, had no data for this time point.
|
Month 9
|
|
Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Month 12
Time Frame: Month 12
|
Following are ECOG grades.
0: Fully active, perform all pre-disease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature.
2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours.
3: Capable of limited selfcare, confined to bed or chair >50% of waking hours.
4: Completely disabled, not capable of any selfcare, totally confined to bed or chair.
5: Dead.
Participants in "Not reported" category were on study, had no data for this time point.
|
Month 12
|
|
Correlation Between Sunitinib-induced Hypertension and Tumor Response to Treatment (PFS)
Time Frame: Baseline to date of first documentation of response to treatment (up to 12 months)
|
Sunitinib-induced hypertension was determined using blood pressure recorded at each postbaseline visit.
Once participants were identified as having sunitinib-induced hypertension, they retained that status at subsequent visits.
PFS is the time from start of study treatment to first documentation of tumor response to treatment.
Hazard ratio represents the relationship between sunitinib-induced hypertension and PFS (presence/absence of hypertension).
|
Baseline to date of first documentation of response to treatment (up to 12 months)
|
|
Correlation Between Sunitinib-induced Hypertension and Tumor Response to Treatment (OS)
Time Frame: Baseline to date of death (up to 12 months)
|
Sunitinib-induced hypertension was determined using blood pressure recorded at each postbaseline visit.
Once participants were identified as having sunitinib-induced hypertension, they retained that status at subsequent visits.
OS is the time from start of study treatment to death.
Hazard ratio represents the relationship between sunitinib-induced hypertension and OS.
|
Baseline to date of death (up to 12 months)
|
|
Percentage of Participants With Hypothyroidism
Time Frame: Baseline, Months 3, 6, 9, 12
|
TSH and FT4 levels were measured and hypothyroidism was defined as a TSH level >5.0 mIU/L at that time point.
|
Baseline, Months 3, 6, 9, 12
|
|
Percentage of Participants With Hypertension
Time Frame: Baseline, Week 6, Months 3, 6, 9, 12
|
Hypertension was defined as follows.
Grade 1: Asymptomatic, transient (less than [<]24 hours) increase by >20mm Hg (diastolic) or to >150/100 mm Hg if previously within normal limits (WNL).
Grade 2: Recurrent or persistent (24 hours or more) or symptomatic increase by >20 mm Hg (diastolic) or to >150/100 mm Hg if previously WNL.
Grade 3: Requiring >1 drug or more intensive therapy than previously.
Grade 4: Life-threatening.
Grade 5: Death.
|
Baseline, Week 6, Months 3, 6, 9, 12
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Summary of Adverse Events for Participants Who Required Dose Modification
Time Frame: Baseline up to 12 months
|
Adverse events (AEs) or treatment-emergent adverse events (TEAEs) were defined as newly occurring or worsening after first dose.
Study drug modifications included reduced dose or temporary discontinuation of treatment.
|
Baseline up to 12 months
|
|
Percentage of Participants With Treatment-emergent Hypertension, by Common Terminology Criteria for Adverse Events (CTCAE) Grade
Time Frame: Baseline up to 12 months
|
Sunitinib-induced hypertension: not present at baseline but developed through the study, or if present at baseline increased by more than (>) 20% during the study.
Grade 1: Asymptomatic, transient (less than [<]24 hours) increase by >20 millimeters of Mercury (mm Hg) (diastolic) or to >150/100 mm Hg if previously within normal limits (WNL); Grade 2: Recurrent or persistent (>=24 hours) or symptomatic increase by >20 mm Hg (diastolic) or to >150/100 mm Hg if previously WNL; Grade 3: Requiring >1 drug or more intensive therapy than previously; Grade 4: Life-threatening; Grade 5: Death.
|
Baseline up to 12 months
|
|
Percentage of Participants Responding to Treatment
Time Frame: 12 months
|
Response categories for target lesions: Complete response (CR): Disappearance of all target lesions; Partial response (PR): At least a 30% decrease in the sum of the longest dimensions, reference=baseline sum of longest dimensions; Progressive disease (PD): At least a 20% increase in the sum of the longest dimensions, or the appearance of 1 or more new lesions; Stable disease (SD): Not sufficient shrinkage to qualify for PR, not sufficient increase to qualify for PD; Reference for PD and SD: smallest sum of longest dimensions since treatment started.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
Other Study ID Numbers
- A6181171
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.